NCT06490003 Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
| NCT ID | NCT06490003 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Esophageal Squamous Cell Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2004-06-01 |
| Primary Completion | 2026-06-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2004-06-01 with a primary completion date of 2026-06-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.
Eligibility Criteria
Inclusion Criteria: 1. Patients who had histologically confirmed esophageal squamous cell carcinoma. 2. Patients who had undergone chemotherapy. 3. Patients receiving initial chemotherapy 4. Written informed consent following full study information is provided to the patient. Exclusion Criteria: 1. Patients for whom a preoperative biopsy sample cannot be obtained 2. Patients who cannot assess at 2 months later after chemotherapy. 3. Patients with multiple cancers.
Contact & Investigator
Koichi Takiguchi, PhD
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT06490003 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Esophageal Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06490003 currently recruiting?
Yes, NCT06490003 is actively recruiting participants. Contact the research team at AJGOEL@COH.ORG for enrollment information.
Where is the NCT06490003 trial being conducted?
This trial is being conducted at Chūō, Japan.
Who is sponsoring the NCT06490003 clinical trial?
NCT06490003 is sponsored by City of Hope Medical Center. The principal investigator is Koichi Takiguchi, PhD at City of Hope Medical Center. The trial plans to enroll 150 participants.